title: [The efficacy of rinopront for the treatment of acute and chronic rhinitis in the children].
abstract: The objective of the present study was to estimate the therapeutic efficacy of rinopront used to treat inflammatory diseases of the nasopharynx in the children. The study included 32 patients at the age between 12 and 14 years presenting with various forms of acute and chronic rhinitis. The children with infectious inflammatory rhinitis with concomitant catarrhal maxillary sinusitis and pronounced symptoms of rhino-conjunctival syndrome recovered within 4-5 days after the initiation of rhinopront therapy. The patients presenting with vasomotor and all-the-year-round allergic rhinitis needed two courses of treatment (5 days each) to recover. The duration of treatment of mild seasonal rhinitis was 4 days whereas the moderately severe disease required the second 5-day course of therapy to be performed to arrest the disease activity.
authors.forename: V R
authors.initials: VR
authors.lastname: Chistiakova
authors.forename: L L
authors.initials: LL
authors.lastname: Miasnikov
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D015523:Maxillary Sinusitis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000009:adverse effects; D009297:Nasal Mucosa / Q000187:drug effects*; D010656:Phenylephrine / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D011725:Pyridines; D010656:Phenylephrine; C004649:carbinoxamine